DISCUSSION ON PADO 3 IMPLEMENTATION

Organized by the International AIDS Society's (IAS's) Industry Liaison Forum (ILF)
in collaboration with the World Health Organization (WHO)

Thursday, 23 November 2017 –10:00-11:00 EST / **16:00-17:00 CET** / 20:30-21:30 IST

Virtual brainstorming session (please see details on page 2)

Almost one year has passed since the PADO 3 meeting, which took place in December 2016 (see meeting report here). Over the past year, more evidence was generated for some drugs included in the priority list and additional information is available to inform the feasibility and timing of some of the prioritized products. Because of this, the PADO 3 list will be reviewed in the coming month with a specific focus on its implementation. This review will take place with consideration for outcomes of the CADO 3 meeting, thereby taking the opportunity to review alignment with drug optimization efforts for adults. These processes will inform the upcoming WHO guidelines review (planned for Q2 2018).

In this context, the objectives of this special feedback session with the ARV manufacturing industry will be to:

- Obtain feedback on the PADO 3 list and discuss key considerations for its implementation
- Discuss ideas to further fast track research and development of priority paediatric ARV formulations.

Please join us for this interactive conference call (register here).

16:00 CET 5 minutes	**Welcome and introduction** Sébastien Morin (IAS)
16:05 CET 10 minutes	**PADO 3 – Review of priority list implementation** Martina Penazzato (WHO)
16:15 CET 40 minutes	**Brainstorming session** Facilitated by Sébastien Morin (IAS) & Martina Penazzato (WHO)
16:55 CET 5 minutes	**Closing remarks** Sébastien Morin (IAS)

Please refer to the ILF guidance on "Key considerations: Compliance with competition rules" (here) for basic rules of engagement for this meeting.